MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
TEM stock logo

TEM

Tempus AI, Inc.

$50.63
1.81
 (3.71%)
Exchange:  NASDAQ
Market Cap:  8.836B
Shares Outstanding:  160.708M
Delayed data
Calculate TEM Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Eric Lefkofsky
Full Time Employees:  2400
Address: 
600 West Chicago Avenue
Chicago
IL
60654
US
Website:  https://www.tempus.com
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers “Insights,” a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its “Trials” program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: “Next”; “Algos,” a collection of algorithm-driven tests focused on oncology; “Hub,” a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and “Lens,” a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue531,822693,3981,271,789
Gross Profit286,175381,113885,687
EBITDA-133,328-610,417-222,357
Operating Income-196,083-691,082-238,635
Net Income-214,118-705,809-245,028

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets564,052926,1162,274,838
Total Liabilities1,946,215869,7771,783,512
Total Stockholders Equity-1,382,16356,339491,326
Total Debt488,142468,094815,705
Cash and Cash Equivalents165,767340,954604,787

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-214,339-189,045-218,090
Capital Expenditure-34,608-22,1210
Free Cash Flow-248,947-211,166-218,090
Net Income-214,118-705,809-245,028
Net Change in Cash-137,124175,2280

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)3,037,560.508Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)3,201,742.708Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)3,122,515.967Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-1,854,332.029Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-1,759,243.716Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-1,808,446.804Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)470,723.662Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)504,077.791Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)487,982.768Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,261,324.866Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)2,383,551.005Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)2,324,570.320Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)2.800Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)2.890Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)2.700Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)6Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
693.398M  ?P/S
 (TTM)
: 
5.94
?Net Income
 (TTM)
: 
-705809000  ?P/E
 (TTM)
: 
-27.42
?Enterprise Value
 (TTM)
: 
8.396B  ?EV/FCF
 (TTM)
: 
-38.78
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.7  ?ROIC
 (TTM)
: 
-0.13
?Net Debt
 (TTM)
: 
19.831M  ?Debt/Equity
 (TTM)
: 
1.96
?P/B
 (TTM)
: 
19.95  ?Current Ratio
 (TTM)
: 
3.31

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about TEM valuation

Is Tempus AI, Inc. (TEM) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Tempus AI, Inc. (TEM) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is TEM a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TEM trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is TEM’s P/E ratio?

You can see TEM’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for TEM?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is TEM a good long-term investment?

Whether TEM fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

TEM

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.71
MARKETSnap

Trading Metrics:

Open: 47.74   Previous Close: 48.82
Day Low: 47.62   Day High: 52.35
Year Low: 41.73   Year High: 104.32
Price Avg 50: 49.3   Price Avg 200: 65.33
Volume: 3.601M   Average Volume: 5.663M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Tempus AI: A Unique AI Business Model With Asymmetric Upside
09-06-2026 06:36
Tempus AI: A Unique AI Business Model With Asymmetric Upside
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
09-06-2026 06:00
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08-06-2026 16:58
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
29-05-2026 09:15
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
Tempus AI: Taking Advantage Of Investor Myopia
22-05-2026 09:43
Tempus AI: Taking Advantage Of Investor Myopia
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
08-05-2026 13:25
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read